Clay Siegall is the CEO, among the founder and president of Seattle Genetics. He studied his bachelor’s degree in zoology at the Maryland University, and PhD from the University of George Washington majored in Genetics. Before co-founding the Seattle Genetics, Clay Siegall worked in National Health Institute from 1988-1991, National Cancer Institute and Bristol-Myers Squibb Research Institute in the year 1988-1991. Siegall is a member of the Board of Directors of a biotechnology company, Alder Biopharmaceuticals. He owns 15 patents and also, he has published over 70 publications.

Since the foundation of Seattle Genetics in 1998, the company under the leadership of Clay Siegall has constructed several antibody cancer therapy drugs one of them being Adcetris, approved in 2011 by the Food and Drug Administration of the United States. Seattle Genetics is the Washington largest biotech company with approximately 900 employees and a market value of over $10 billion with a goal of becoming a pharmaceutical company someday.

Seattle Genetics for years has been specializing in the study, manipulating and packaging of drugs. Among the companies’ drug, it latest discovery was Adcetris, a Hodgkin lymphoma drug that kills the spread of the lymph cancer. Before the discovery of this drug, Siegall sold to Takeda Oncology Seattle commercial international rights for them to raise enough capital to invest in the drug. During its partnership with the Takeda Oncology, Seattle Genetics learnt more about the global market and recently started up an international marketing office in Switzerland to aid its global marketing.

Seattle Genetics lately has been focusing on the ADC (Antibody Drug Conjugate), a drug that aims at the body’s antigen. These drugs mainly work to kill the Lymph cancer cells in the sense that they surround the cell, produce some toxin to those cells and kill them. These drugs help in the reduction of damage that accompanies chemotherapy during cancer treatments. Of its eleven drugs that the company has produced, four of them have high chances of making big sales in the future.

Siegall’s enthusiasm and success are partly from his mentor Art Levinson, co-founder of Genentech and Apple Incorporation current chairman. Clay Siegall seriously studied the structure of Genentech and its internal functions, and from that developed ideas to start his firm. Not only did he learn how to structure a company, but he also decided that he will not only depend on one drug as most biotech firms do. As a result, he has developed several drugs to tackle the cancer pandemic on the globe.